Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer.

Saved in:
Bibliographic Details
Title: Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer.
Authors: Ge GH; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Guo S; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Li TT; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Wang YP; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Liu LR; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Yu WH; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Hu H; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Zheng YM; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Yan JH; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Sun YH; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China., Liang JW; Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, Hainan Provincial Key Laboratory of Research and Development on Tropical Herbs, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou 571199, Hainan, China; School of Pharmacy, Hainan Medical University, Haikou 571199, Hainan, China., Meng FH; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China. Electronic address: fhmeng@cmu.edu.cn., Zhang TJ; School of Pharmacy, Key Laboratory of Research, and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China; Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, Hainan Provincial Key Laboratory of Research and Development on Tropical Herbs, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou 571199, Hainan, China. Electronic address: tjzhang@cmu.edu.cn.
Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2025 Dec 01; Vol. 128, pp. 130362. Date of Electronic Publication: 2025 Aug 05.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3405 (Electronic) Linking ISSN: 0960894X NLM ISO Abbreviation: Bioorg Med Chem Lett Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1464-3405
DOI:10.1016/j.bmcl.2025.130362